Skip to main content

Curevac N.V.(CVAC-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low4.57
Day High4.67
Open:4.57
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Tipranks
CureVac’s CVGBM Brain Cancer Vaccine Trial Reaches Completion: What It Means for CVAC Investors
Tipranks
CureVac Completes BioNTech-Driven Reorganization and Moves to Delist from Nasdaq
Tipranks
CureVac Reports Q3 2025 Financial Results and Updates
ACCESS Newswire
CureVac Announces Voting Results of Extraordinary General Meeting
Tipranks
CureVac Reports Q3 2025 Financials and BioNTech Transaction Progress
ACCESS Newswire
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
Tipranks
CureVac’s New mRNA Study: A Potential Game-Changer in Lung Cancer Treatment
Tipranks
CureVac Announces Extraordinary Meeting for Merger with BioNTech
Tipranks
CureVac’s Strategic Moves and Financial Highlights in 2025
Tipranks
Leerink Partners Keeps Their Hold Rating on CureVac (CVAC)
Tipranks
CureVac Reports Financial Losses in Mid-2025
ACCESS Newswire
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
Tipranks
CureVac Resolves Patent Litigation with Pfizer/BioNTech
Tipranks
UBS downgrades CureVac (CVAC) to a Hold
ACCESS Newswire
CureVac Announces Voting Results of General Meeting
Tipranks
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), CureVac (CVAC) and AnaptysBio (ANAB)
Tipranks
CureVac (CVAC) was downgraded to a Hold Rating at Citizens JMP
Tipranks
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories
Tipranks
M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal
Tipranks
M&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer Pipeline
Tipranks
Citizens JMP Remains a Buy on CureVac (CVAC)
Tipranks
Bank of America Securities Sticks to Their Sell Rating for CureVac (CVAC)
Tipranks
CureVac (CVAC) Receives a Hold from Leerink Partners
ACCESS Newswire
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
ACCESS Newswire
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
Tipranks
CureVac Stock (CVAC) Dips Despite Promising Treatment Pipeline
ACCESS Newswire
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
ACCESS Newswire
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
ACCESS Newswire
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Tipranks
CureVac (CVAC) Gets a Hold from Leerink Partners
ACCESS Newswire
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
ACCESS Newswire
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

Profile

CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.